-transparent.png){kind=logo}
Megakaryocyte growth and development factor (MGDF) administered intraperitoneally (IP) to mice causes a dose-dependent thrombocytosis accompanied by a decrease in mean platelet volume. MGDF increases the number of megakaryocytes in the bone marrow and spleen. MGDF does not affect the circulating number of leukocytes. Carboplatin, a chemotherapeutic agent that causes thrombocytopenia in humans, administered to mice as a single IP injection at a nonlethal dose causes a significant, but reversible thrombocytopenia. The carboplatin-induced thrombocytopenia is accompanied by an increase in circulating endogenous MGDF that precedes the return of circulating platelets to a normal level. MGDF mRNA is constitutively present in the liver. After carboplatin treatment, hepatic MGDF mRNA does not increase in concordance with circulating MGDF. Circulating soluble MGDF receptor levels (c-mpl) do not change significantly during the course of carboplatin-induced thrombocytopenia. MGDF injected IP once daily beginning 1 day after injection of carboplatin reverses carboplatin-induced thrombocytopenia in a dose-dependent fashion. The normalization of circulating platelet numbers in carboplatin plus MGDF-treated mice is accompanied by a normalization of megakaryocyte numbers in the bone marrow. In conclusion, MGDF, by increasing the number of marrow megakaryocytes and circulating platelets is an effective therapy for carboplatin-induced thrombocytopenia in mice.
T R Ulich, and
J del Castillo, and
S Yin, and
S Swift, and
D Padilla, and
G Senaldi, and
L Bennett, and
J Shutter, and
J Bogenberger, and
D Sun
December 1995,
Blood,
T R Ulich, and
J del Castillo, and
S Yin, and
S Swift, and
D Padilla, and
G Senaldi, and
L Bennett, and
J Shutter, and
J Bogenberger, and
D Sun
October 1998,
The Annals of thoracic surgery,
T R Ulich, and
J del Castillo, and
S Yin, and
S Swift, and
D Padilla, and
G Senaldi, and
L Bennett, and
J Shutter, and
J Bogenberger, and
D Sun
November 1996,
Stem cells (Dayton, Ohio),
T R Ulich, and
J del Castillo, and
S Yin, and
S Swift, and
D Padilla, and
G Senaldi, and
L Bennett, and
J Shutter, and
J Bogenberger, and
D Sun
December 1996,
Bone marrow transplantation,
T R Ulich, and
J del Castillo, and
S Yin, and
S Swift, and
D Padilla, and
G Senaldi, and
L Bennett, and
J Shutter, and
J Bogenberger, and
D Sun
June 2000,
Pediatric hematology and oncology,
T R Ulich, and
J del Castillo, and
S Yin, and
S Swift, and
D Padilla, and
G Senaldi, and
L Bennett, and
J Shutter, and
J Bogenberger, and
D Sun
March 2000,
The Journal of pharmacy and pharmacology,
T R Ulich, and
J del Castillo, and
S Yin, and
S Swift, and
D Padilla, and
G Senaldi, and
L Bennett, and
J Shutter, and
J Bogenberger, and
D Sun
February 1998,
Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis,
T R Ulich, and
J del Castillo, and
S Yin, and
S Swift, and
D Padilla, and
G Senaldi, and
L Bennett, and
J Shutter, and
J Bogenberger, and
D Sun
January 1997,
European journal of histochemistry : EJH,
T R Ulich, and
J del Castillo, and
S Yin, and
S Swift, and
D Padilla, and
G Senaldi, and
L Bennett, and
J Shutter, and
J Bogenberger, and
D Sun
June 1995,
The Journal of clinical investigation,
T R Ulich, and
J del Castillo, and
S Yin, and
S Swift, and
D Padilla, and
G Senaldi, and
L Bennett, and
J Shutter, and
J Bogenberger, and
D Sun
January 1974,
British journal of haematology,
